Hikma Pharmaceuticals PLC (LSE: HIK) has disclosed that Bassam Kanaan, a Person Discharging Managerial Responsibilities at the company, sold a combined total of 66,941 ordinary shares across two separate transactions on 5 and 6 November 2026, raising approximately £1,130,541.72 in aggregate. The disposals were conducted on the London Stock Exchange and notified to the market on 9 November 2026 under UK Market Abuse Regulation. Such PDMR transactions are closely watched by investors as a signal of insider sentiment towards the company's near-term outlook.

Key Points

  • Hikma Pharmaceuticals PLC (LSE: HIK), dual-listed on the London Stock Exchange and Nasdaq Dubai
  • PDMR Bassam Kanaan disposed of 66,941 ordinary shares of 10 pence each across two transactions on 5 and 6 November 2026
  • First disposal: 61,941 shares at £16.92 each, totalling £1,048,041.72; second disposal: 5,000 shares at £16.50 each, totalling £82,500
  • Investors may be watching whether further PDMR activity follows given the scale of the disposal

Bassam Kanaan Disposes of 61,941 Hikma Shares at £16.92 on 5 November 2026

The larger of the two transactions took place on 5 November 2026, when Bassam Kanaan sold 61,941 ordinary shares in Hikma Pharmaceuticals PLC at a price of £16.92 per share on the London Stock Exchange. The aggregate value of this single disposal amounted to £1,048,041.72, according to the announcement. The shares are identified by ISIN code GB00B0LCW083 and carry a nominal value of 10 pence each. This transaction alone accounts for the majority of the total value disclosed across both dealings reported in the notification.

Second Share Sale of 5,000 Shares at £16.50 Completed the Following Day

A second, smaller disposal followed on 6 November 2026, with Kanaan selling a further 5,000 ordinary shares at £16.50 per share, also on the London Stock Exchange, generating proceeds of £82,500. The slight reduction in price between the two transactions — from £16.92 to £16.50 — is noted in the announcement without further explanation. Both transactions are classified as initial notifications under Article 19(1) of UK MAR, as retained through the European Union (Withdrawal) Act 2018, and were disclosed by Group Company Secretary Helen Middlemist.

Hikma's Dual Listing and Pharmaceutical Business Provide Context for PDMR Disclosure

Hikma Pharmaceuticals PLC is a multinational pharmaceutical company listed on both the London Stock Exchange and Nasdaq Dubai under the ticker HIK, with a LEI of 549300BNS685UXH4JI75. The group operates across injectable, branded, and generic medicines segments, serving markets across the United States, Middle East, North Africa, and Europe. PDMR share disposals of this scale are required to be disclosed publicly under UK market transparency rules, allowing investors to monitor changes in managerial shareholdings. The announcement does not provide information regarding Kanaan's remaining shareholding following these transactions.